Arleigh McCurdy

3.1k total citations · 1 hit paper
92 papers, 1.8k citations indexed

About

Arleigh McCurdy is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Arleigh McCurdy has authored 92 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Hematology, 63 papers in Molecular Biology and 50 papers in Oncology. Recurrent topics in Arleigh McCurdy's work include Multiple Myeloma Research and Treatments (80 papers), Protein Degradation and Inhibitors (43 papers) and Cancer Treatment and Pharmacology (26 papers). Arleigh McCurdy is often cited by papers focused on Multiple Myeloma Research and Treatments (80 papers), Protein Degradation and Inhibitors (43 papers) and Cancer Treatment and Pharmacology (26 papers). Arleigh McCurdy collaborates with scholars based in Canada, United States and United Kingdom. Arleigh McCurdy's co-authors include Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Suzanne R. Hayman, Robert A. Kyle, Francis K. Buadi, Shaji Kumar, David Dingli, Prashant Kapoor and Nelson Leung and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Arleigh McCurdy

83 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

2013 957 citations Shaji Kumar, Angela Dispenzieri et al. profile →

Peers

Arleigh McCurdy

HEMAT

ONCOL

GENET

IMMUN

Andrew Cakana United States

Lionel Karlin France

Olivier Decaux France

Cyrille Hulin France

Karthik Ramasamy United Kingdom

Maria Teresa Petrucci Italy

Joth Jacobson United States

Zvenyslava Masliak Poland

Raymond Thertulien United States

Leonard T. Heffner United States

Andrew Cakana United States

Arleigh McCurdy

1.5k ×1.0

HEMAT

1.4k ×1.1

948 ×1.0

ONCOL

299 ×1.2

GENET

47 ×0.4

IMMUN

Citations per year, relative to Arleigh McCurdy Arleigh McCurdy (= 1×) peers Andrew Cakana

Countries citing papers authored by Arleigh McCurdy

Since Specialization

Citations

This map shows the geographic impact of Arleigh McCurdy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arleigh McCurdy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arleigh McCurdy more than expected).

Fields of papers citing papers by Arleigh McCurdy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arleigh McCurdy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arleigh McCurdy. The network helps show where Arleigh McCurdy may publish in the future.

Co-authorship network of co-authors of Arleigh McCurdy

This figure shows the co-authorship network connecting the top 25 collaborators of Arleigh McCurdy. A scholar is included among the top collaborators of Arleigh McCurdy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arleigh McCurdy. Arleigh McCurdy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Venner, Christopher P., Peter Duggan, Kevin Song, et al.. (2024). Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database. Transplantation and Cellular Therapy. 30(9). 889–901. 1 indexed citations

Sandhu, Irwindeep, Michael P. Chu, Kathryn N. Rankin, et al.. (2024). Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population. Blood. 144(Supplement 1). 1912–1912.

Mian, Hira, Hsien Seow, Matthew C. Cheung, et al.. (2024). A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma. The Oncologist. 29(6). 519–526. 2 indexed citations

Chakraborty, Rajshekhar, Bram Rochwerg, Alissa Visram, et al.. (2024). Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Advances. 8(23). 5993–6002. 8 indexed citations

McCurdy, Arleigh, Donna Reece, Martha Louzada, et al.. (2024). Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood Cancer Journal. 14(1). 155–155. 2 indexed citations

Visram, Alissa, Kelvin Chan, Hsien Seow, et al.. (2024). Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica. 110(1). 228–233.

Haider, Imran, Darryl P. Leong, Martha Louzada, et al.. (2024). Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 144(Supplement 1). 703–703. 1 indexed citations

Visram, Alissa, Hsien Seow, Gregory R. Pond, et al.. (2023). Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142(Supplement 1). 3774–3774. 1 indexed citations

McCurdy, Arleigh, Donna Reece, Christopher P. Venner, et al.. (2023). Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 142(Supplement 1). 3364–3364. 1 indexed citations

10.

McCurdy, Arleigh & Alissa Visram. (2022). The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma. Current Hematologic Malignancy Reports. 17(6). 306–318. 6 indexed citations

11.

Murthy, Sanjay K., Arleigh McCurdy, Marc Carrier, & Jeffrey D. McCurdy. (2020). Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. Thrombosis Research. 194. 26–32. 11 indexed citations

12.

Atkins, Harold, et al.. (2020). Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma. Current Oncology. 27(2). 81–85. 5 indexed citations

13.

McCurdy, Arleigh, et al.. (2019). The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. Hematology Transfusion and Cell Therapy. 41(4). 285–291. 2 indexed citations

14.

Li, Tony, Ranjeeta Mallick, Arleigh McCurdy, et al.. (2018). Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 19(2). 68–72.

15.

McCudden, Christopher R., et al.. (2017). Synoptic reporting for protein electrophoresis and immunofixation. Clinical Biochemistry. 51. 21–28. 9 indexed citations

16.

McCudden, Christopher R., et al.. (2017). Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis. Clinical Biochemistry. 51. 61–65. 8 indexed citations

17.

Grogan, Martha, Morie A. Gertz, Arleigh McCurdy, et al.. (2016). Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World Journal of Transplantation. 6(2). 380–380. 51 indexed citations

18.

Cordes, Stefan, Morie A. Gertz, Francis K. Buadi, et al.. (2015). Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation & Fibrinolysis. 27(1). 101–108. 9 indexed citations

19.

Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations

20.

Dispenzieri, Angela, Morie A. Gertz, Martha Q. Lacy, et al.. (2013). Therapeutic Strategies For Initial Treatment Of AL Amyloidosis: Implications Of Therapy and Response On Outcome. Blood. 122(21). 3343–3343. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact